cIAP2 (API2, BIRC3, HIAP2, MIHC) is a member of the family of inhibitor of apoptosis proteins (IAP).
IAPs suppress mitochondria dependent and independent apoptosis by binding to and inhibiting caspases through their BIR domains (reviewed in Liston et al, 2003; Wright and Duckett, 2005).
Resistance towards apoptosis is a hallmark of cancer cells, and overexpression of IAPs can contribute to the development of cancer though inhibiting apoptosis.
In addition to at least one BIR domain, some IAP members also have a RING-type finger motif at their carboxyl-terminal.
The RING finger domain of several IAPs, including cIAP2, have E3 ubiquitin ligase activity and target the degradation of Smac/DIABLO through ubiquitination.
Smac/DIABLO is a death inducer and functions by inhibiting IAP-caspase interactions, thereby promoting apoptosis.
Degradation of cell death inducers like Smac/DIABLO is thought to be a conserved mechanism by which IAPs enhance their anti-apoptotic activity, thereby promoting cell survival.
The IAPs, including cIAP2, have widespread tissue protein expression, with expression levels and subcellular localization patterns differing depending on the cell lineage (see Vischioni et al.
2005 for a comprehensive study).
cIAP2-MALT (API2-MALT1) fusion proteins have been implicated in the molecular pathology of mucosa associated lymphoid tissue (MALT) lymphoma (reviewed in Hosokawa, 2005).
AP12-MALT fusion proteins are found in a subset of patients with MALT lymphoma.
They are generated by chromosomal translocations whereby the N-terminal portion of AP12 (including the BIR domains) is linked to the C-terminal portion of MALT1 (containing at least an immunoglobulin-like domain and a caspase domain).
Several variants of the API2-MALT1 fusion proteins can occur in MALT1 lymphoma patients depending on the chromosomal breakpoints.
It is thought that AP12-MALT1 can enhance the activation of NK-kB signaling, which may be relevant to the pathology of MALT lymphomas.
Users should keep in mind that the actual amino acid length of AP12-MALT1 fusion proteins may vary depending on the chromosomal breakpoints
Applications:Suitable for use in Western Blot, Immunoprecipitation and Immunohistochemistry.
Other applications not tested.
Recommended Dilutions:Western Blot: 1:1000-1:2000Immunohistochemistry (Frozen): 1:10-1:500Immunohistochemistry (Paraffin): 1:1000-1:5000Immunoprecipitation: 1:50-1:200Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4°C for short-term only.
Aliquot to avoid repeated freezing and thawing.
Store at -20°C.
Aliquots are stable for 12 months after receipt.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：50ul
Host：rabbit
Source Antibody：human
Grade：Serum
Purity：Serum
Form：Supplied as a liquid, 0.05% sodium azide.
Specificity：Recognizes human BIRC3. This antibody should also recognize AP12-MALT1 fusion proteins assuming that they contain the cIAP2 peptide sequence (QDFSALMRSSYHCAMNNENAR)
Isotype：IgG
Calc Applications Abbrev：IHC IP WB
Calc Crossreactivity：Hu
Immunogen：Synthetic peptide corresponding to amino acids 152-172 (QDFSALMRSSYHCAMNNENAR) of human BIRC3.
